Therapeutics News and Research

RSS

New technique may help scientists probe mysteries of many different stem cells

Researchers at the Salk Institute have been able to genetically incorporate "unnatural" amino acids, such as those emitting green fluorescence, into neural stem cells, which then differentiate into brain neurons with the incandescent "tag" intact.

8 Jul 2011

New target could halt growth of glioblastoma

Researchers have uncovered a new target that could stop the growth of glioblastoma, a deadly form of brain cancer.

8 Jul 2011

InVivo files biopolymer scaffold IDE with FDA to initiate spinal cord injury clinical trial

InVivo Therapeutics today announced that the Company has submitted an Investigational Device Exemption (IDE) to the U.S. Food and Drug Administration (FDA) for a proprietary biopolymer scaffolding device to protect and support spinal tissue and prevent secondary injury, including inflammation and glial scarring, following traumatic spinal cord injury.

8 Jul 2011

Final Atlantis space trip may open new era of research into infectious diseases

On July 8, at approximately 11:26 a.m. EDT, the space shuttle Atlantis will streak skyward from the Kennedy Space Center's launch pad 39A, for one last mission. While the STS-135 flight marks the end of the space shuttle's glory days, its final trip may open a new era of research into infectious diseases, thanks to space bound experiments conducted by Dr's. Cheryl Nickerson, and Roy Curtiss III, along with their colleagues at Arizona State University's Biodesign Institute.

7 Jul 2011

Zinc oxide nanowire waveguide lasers could kill viruses, increase DVD storage capacity

A team led by a professor at the University of California, Riverside Bourns College of Engineering has made a discovery in semiconductor nanowire laser technology that could potentially do everything from kill viruses to increase storage capacity of DVDs.

6 Jul 2011

Study highlights importance of mRNA translation in aging process

When researchers at the Buck Institute dialed back activity of a specific mRNA translation factor in adult nematode worms they saw an unexpected genome-wide response that effectively increased activity in specific stress response genes that could help explain why the worms lived 40 percent longer under this condition.

6 Jul 2011

New biological insights into fat tissue

For better or worse, a popular class of anti-diabetic drugs does more than lower blood sugar. One known as rosiglitazone has been in the spotlight for its possible link to increased cardiovascular events, but it also seems to come with unexplained vascular benefits and an unwelcome tendency for weight gain.

6 Jul 2011

Positive topline results from Alkermes ALKS 9070 phase 1b study for schizophrenia

Alkermes, Inc. today announced positive topline results from a phase 1b, double-blind, randomized, placebo-controlled study of ALKS 9070 in patients with schizophrenia.

30 Jun 2011

Premature ejaculation treatment market to reach over $1.3 billion by 2017

In 2010 the premature ejaculation treatment market was estimated to be worth $684 million, according to a new research report available on companiesandmarkets.com.

30 Jun 2011

Sorbent expands $36M Series B financing

Sorbent Therapeutics, a private biopharmaceutical company developing therapies for cardiovascular and renal disorders, announced today that it has expanded the Company's Series B financing from September 2010 by $36 million.

30 Jun 2011

Recombinant attenuated Salmonella vaccines hold promise against infectious diseases

A powerful new class of therapeutics, known as recombinant attenuated Salmonella vaccines (RASV), holds great potential in the fight against fatal diseases including hepatitis B, tuberculosis, cholera, typhoid fever, AIDS and pneumonia.

30 Jun 2011

UNC study uses optogenetics to tweak brain wiring responsible for drug addiction behaviors

Using a combination of genetic engineering and laser technology, researchers at the University of North Carolina at Chapel Hill have manipulated brain wiring responsible for reward-seeking behaviors, such as drug addiction.

30 Jun 2011

Cell Therapeutics to sell $30 million of Preferred Stock and warrants in registered offering

Cell Therapeutics, Inc. today announced that it has entered into an agreement to sell, subject to customary closing conditions, $30 million of shares of its Series 13 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to six institutional investors.

30 Jun 2011

RxMD and GlycoRegImmune enter drug development collaboration

RxMD, Inc., a privately-held, global therapeutics development company, today announced a collaboration agreement with GlycoRegImmune Inc. (GRI) to develop new treatments for inflammatory, autoimmune, and neurodegenerative conditions based on GRI's novel natural killer (NK) T cell targeted technologies.

29 Jun 2011

Amorfix fiscal 2011 net loss decreases to $3,330,437

Amorfix Life Sciences, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced its operational and financial results for the year ended March 31, 2011, as well as financial results for the fourth quarter.

29 Jun 2011

Glybera gene therapy reduces pancreatitis risk in Lipoprotein Lipase Deficiency patients

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today released data showing that its gene therapy Glybera® (alipogene tiparvovec) significantly reduces the risk of pancreatitis in patients with Lipoprotein Lipase Deficiency (LPLD). Pancreatitis, or inflammation of the pancreas, is a major clinical symptom of LPLD.

29 Jun 2011

CTI added to Russell's U.S. indexes

Cell Therapeutics, Inc. announced today that it has been added to the Russell 3000, Russell 2000 and Russell Global Indexes posted by Russell Investments on June 27, 2011.

28 Jun 2011

Scientists discover origin of Barrett's esophagus

Dr Frank McKeon, Senior Group Leader of the Stem Cell and Developmental Biology at A*STAR's Genome Institute of Singapore, and Principal Investigator Dr Wa Xian at A*STAR's Institute of Medical Biology, together with their counterparts from the Harvard Medical School, the Brigham and Women's Hospital in Boston, and the National University of Singapore, have made the striking finding that Barrett's esophagus work, published online in the journal Cell on 24 June 2011, is essential to developing therapeutics for esophageal cancer.

28 Jun 2011

Marshall Edwards' Triphendiol pre-clinical study data now available in Anti-Cancer Drugs website

Marshall Edwards, Inc., an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the publication of results from pre-clinical studies of Triphendiol, a prodrug of the Company's lead drug candidate NV-143, that demonstrate its anti-proliferative activity in pancreatic cancer as both a monotherapy and as a chemosensitizer.

28 Jun 2011

Australian Nobel Prize winner closer to delivering vaccines in food after positive first study in humans

The Australian scientist who won a Nobel Prize for identifying a cancer-causing stomach bacterium, today said a clinical trial had shown that some strains of the bacteria (Helicobacter pylori or H. pylori) were safe and well tolerated in humans.

27 Jun 2011

Therapeutics News and Research

New technique may help scientists probe mysteries of many different stem cells

New target could halt growth of glioblastoma

InVivo files biopolymer scaffold IDE with FDA to initiate spinal cord injury clinical trial

Final Atlantis space trip may open new era of research into infectious diseases

Zinc oxide nanowire waveguide lasers could kill viruses, increase DVD storage capacity

Study highlights importance of mRNA translation in aging process

New biological insights into fat tissue

Positive topline results from Alkermes ALKS 9070 phase 1b study for schizophrenia

Premature ejaculation treatment market to reach over $1.3 billion by 2017

Sorbent expands $36M Series B financing

Recombinant attenuated Salmonella vaccines hold promise against infectious diseases

UNC study uses optogenetics to tweak brain wiring responsible for drug addiction behaviors

Cell Therapeutics to sell $30 million of Preferred Stock and warrants in registered offering

RxMD and GlycoRegImmune enter drug development collaboration

Amorfix fiscal 2011 net loss decreases to $3,330,437

Glybera gene therapy reduces pancreatitis risk in Lipoprotein Lipase Deficiency patients

CTI added to Russell's U.S. indexes

Scientists discover origin of Barrett's esophagus

Marshall Edwards' Triphendiol pre-clinical study data now available in Anti-Cancer Drugs website

Australian Nobel Prize winner closer to delivering vaccines in food after positive first study in humans

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News